• Je něco špatně v tomto záznamu ?

MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells

M. Aristorena, E. Gallardo-Vara, M. Vicen, M. de Las Casas-Engel, L. Ojeda-Fernandez, C. Nieto, FJ. Blanco, AC. Valbuena-Diez, LM. Botella, P. Nachtigal, AL. Corbi, M. Colmenares, C. Bernabeu,

. 2019 ; 20 (12) : . [pub] 20190625

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044721

Grantová podpora
SAF2013-43421-R to CB; SAF2017-83785-R and SAF2014-23801 to ALC Ministerio de Ciencia e Innovación
201920E022 to CB Consejo Superior de Investigaciones Científicas
ISCIII-CB06/07/0038 to CB Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)
SVV-260414 to PN Czech Republic Specific University Research

Upon inflammation, monocyte-derived macrophages (MΦ) infiltrate blood vessels to regulate several processes involved in vascular pathophysiology. However, little is known about the mediators involved. Macrophage polarization is crucial for a fast and efficient initial response (GM-MΦ) and a good resolution (M-MΦ) of the inflammatory process. The functional activity of polarized MΦ is exerted mainly through their secretome, which can target other cell types, including endothelial cells. Endoglin (CD105) is a cell surface receptor expressed by endothelial cells and MΦ that is markedly upregulated in inflammation and critically involved in angiogenesis. In addition, a soluble form of endoglin with anti-angiogenic activity has been described in inflammation-associated pathologies. The aim of this work was to identify components of the MΦ secretome involved in the shedding of soluble endoglin. We find that the GM-MΦ secretome contains metalloprotease 12 (MMP-12), a GM-MΦ specific marker that may account for the anti-angiogenic activity of the GM-MΦ secretome. Cell surface endoglin is present in both GM-MΦ and M-MΦ, but soluble endoglin is only detected in GM-MΦ culture supernatants. Moreover, MMP-12 is responsible for the shedding of soluble endoglin in vitro and in vivo by targeting membrane-bound endoglin in both MΦ and endothelial cells. These data demonstrate a direct correlation between GM-MΦ polarization, MMP-12, and soluble endoglin expression and function. By targeting endothelial cells, MMP-12 may represent a novel mediator involved in vascular homeostasis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044721
003      
CZ-PrNML
005      
20200113081227.0
007      
ta
008      
200109s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms20123107 $2 doi
035    __
$a (PubMed)31242676
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Aristorena, Mikel $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. m.aristorena@ucl.ac.uk. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. m.aristorena@ucl.ac.uk.
245    10
$a MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells / $c M. Aristorena, E. Gallardo-Vara, M. Vicen, M. de Las Casas-Engel, L. Ojeda-Fernandez, C. Nieto, FJ. Blanco, AC. Valbuena-Diez, LM. Botella, P. Nachtigal, AL. Corbi, M. Colmenares, C. Bernabeu,
520    9_
$a Upon inflammation, monocyte-derived macrophages (MΦ) infiltrate blood vessels to regulate several processes involved in vascular pathophysiology. However, little is known about the mediators involved. Macrophage polarization is crucial for a fast and efficient initial response (GM-MΦ) and a good resolution (M-MΦ) of the inflammatory process. The functional activity of polarized MΦ is exerted mainly through their secretome, which can target other cell types, including endothelial cells. Endoglin (CD105) is a cell surface receptor expressed by endothelial cells and MΦ that is markedly upregulated in inflammation and critically involved in angiogenesis. In addition, a soluble form of endoglin with anti-angiogenic activity has been described in inflammation-associated pathologies. The aim of this work was to identify components of the MΦ secretome involved in the shedding of soluble endoglin. We find that the GM-MΦ secretome contains metalloprotease 12 (MMP-12), a GM-MΦ specific marker that may account for the anti-angiogenic activity of the GM-MΦ secretome. Cell surface endoglin is present in both GM-MΦ and M-MΦ, but soluble endoglin is only detected in GM-MΦ culture supernatants. Moreover, MMP-12 is responsible for the shedding of soluble endoglin in vitro and in vivo by targeting membrane-bound endoglin in both MΦ and endothelial cells. These data demonstrate a direct correlation between GM-MΦ polarization, MMP-12, and soluble endoglin expression and function. By targeting endothelial cells, MMP-12 may represent a novel mediator involved in vascular homeostasis.
650    _2
$a zvířata $7 D000818
650    _2
$a kultivované buňky $7 D002478
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a náchylnost k nemoci $7 D004198
650    _2
$a endoglin $x genetika $x metabolismus $7 D000071063
650    _2
$a endoteliální buňky $x metabolismus $7 D042783
650    _2
$a exprese genu $7 D015870
650    _2
$a faktor stimulující granulocyto-makrofágové kolonie $x metabolismus $7 D016178
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x etiologie $x metabolismus $7 D007249
650    _2
$a mediátory zánětu $x metabolismus $7 D018836
650    _2
$a faktor stimulující kolonie makrofágů $x metabolismus $7 D016173
650    _2
$a makrofágy $x imunologie $x metabolismus $7 D008264
650    _2
$a matrixová metaloproteinasa 12 $x metabolismus $7 D053508
650    _2
$a myši $7 D051379
650    _2
$a biologické modely $7 D008954
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gallardo-Vara, Eunate $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. eunate.gallardo@yale.edu. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. eunate.gallardo@yale.edu.
700    1_
$a Vicen, Matej $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. matej.vicen@gmail.com.
700    1_
$a de Las Casas-Engel, Mateo $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. mcasas@cib.csic.es.
700    1_
$a Ojeda-Fernandez, Luisa $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. mluisa.ojeda@gmail.com. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. mluisa.ojeda@gmail.com.
700    1_
$a Nieto, Concepción $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. cnieto@cib.csic.es.
700    1_
$a Blanco, Francisco J $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. fjblanco@ugr.es. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. fjblanco@ugr.es.
700    1_
$a Valbuena-Diez, Ana C $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. ac22vd@hotmail.com. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. ac22vd@hotmail.com.
700    1_
$a Botella, Luisa M $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. cibluisa@cib.csic.es. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. cibluisa@cib.csic.es.
700    1_
$a Nachtigal, Petr $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. nachtigal@faf.cuni.cz.
700    1_
$a Corbi, Angel L $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. acorbi@cib.csic.es.
700    1_
$a Colmenares, María $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. maria.colmenares@cib.csic.es.
700    1_
$a Bernabeu, Carmelo $u Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. bernabeu.c@cib.csic.es. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. bernabeu.c@cib.csic.es.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 20, č. 12 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31242676 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113081559 $b ABA008
999    __
$a ok $b bmc $g 1482990 $s 1083394
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 20 $c 12 $e 20190625 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a SAF2013-43421-R to CB; SAF2017-83785-R and SAF2014-23801 to ALC $p Ministerio de Ciencia e Innovación
GRA    __
$a 201920E022 to CB $p Consejo Superior de Investigaciones Científicas
GRA    __
$a ISCIII-CB06/07/0038 to CB $p Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)
GRA    __
$a SVV-260414 to PN $p Czech Republic Specific University Research
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...